Patents Examined by Traviss C. McIntosh, III
  • Patent number: 10450340
    Abstract: 2-pyrrolino-13-deoxyanthracycline derivatives, medical uses thereof, and a process for making them. A 2-pyrrolino-13-deoxyanthracycline and a 13-deoxyanthracycline can be administered to a patient simultaneously or sequentially in amounts to produce a synergistic therapeutic effect with increased potency and efficacy, compared to the sum of the effects of each drug when administered alone. A composition or preparation of a 2-pyrrolino-13-deoxyanthracycline and a 13-deoxyanthracycline for producing a potent anticancer therapeutic effect is also provided.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: October 22, 2019
    Assignee: MONOPAR THERAPEUTICS INC.
    Inventors: Richard Olson, Gerald Walsh
  • Patent number: 10435429
    Abstract: Provided herein are 5-fluorouridine monophosphate cyclic triester compounds, their preparation and their uses, such as treating hepatocellular carcinoma and other types of cancer.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: October 8, 2019
    Assignee: Nucorion Pharmaceuticals, Inc.
    Inventor: Lin Zhi
  • Patent number: 10435425
    Abstract: Disclosed herein a sialyl donor and its use for the synthesis of gangliosides. The sialyl donor has the structure of, wherein, R1 and R2 are independently benzoyl, toluenesulfonyl, pivaloyl or acetyl optionally substituted with a halogen; and R3 is acetyl or —(O)CCH2OH. In one preferred embodiment, in the sialyl donor of formula (I), R is acetyl. Also disclosed herein is a method of synthesizing a sialoside. The method comprises steps of: coupling the sialyl donor of formula (I) with a glycosyl acceptor having a primary hydroxyl group in the presence of N-iodosuccinimide (NIS) and trifluoromethanesulfonic acid (TfOH) under suitable conditions; and isolating the sialoside, which has an ?-glycosidic linkage. According to preferred embodiments, the coupling is conducted in a solvent selected from the group consisting of, CH3CN, CH3Cl, and CH2Cl2 at a temperature between ?20° C. to ?60° C.
    Type: Grant
    Filed: July 14, 2018
    Date of Patent: October 8, 2019
    Assignee: Chung Yuan Christian University
    Inventors: Yow-Fu Tsai, Yu-Fa Wu
  • Patent number: 10428105
    Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions for treatment of viral infections, especially HRV.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: October 1, 2019
    Assignee: Novartis AG
    Inventors: Martijn Fenaux, Oliver Saunders, Fumiaki Yokokawa, Weidong Zhong
  • Patent number: 10414788
    Abstract: A group of substituted thienopyrrolopyrimidine ribonucleosides of general formula I, in which R shows strong cytostatic and cytotoxic activities preferably against cancer cell lines of broad spectrum of diseases including tumors of various histogenetic origin.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: September 17, 2019
    Assignees: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., UNIVERZITA PALACKEHO V OLOMOUCI
    Inventors: Michal Hocek, Michal Tichy, Marian Hajduch, Petr Dzubak
  • Patent number: 10406172
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: September 10, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Peter Eickelmann, Michael Mark, Leo John Seman, Leo Thomas, Uli Broedl, Rolf Grempler
  • Patent number: 10398715
    Abstract: Disclosed are methods for enhancing learning and/or memory, enhancing memory acquisition, memory retention and recall by inducing a higher long-term potentiation in hippocampal neuronal synapsis in individuals. The methods include administration of 2-fucosyl-lactose to an individual.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: September 3, 2019
    Assignee: ABBOTT LABORATORIES
    Inventors: Enrique Vazquez Hernandez, Ricardo Rueda Cabrera, Rachael Buck, Maria Ramirez Gonzalez, Alejandro Barranco Perez
  • Patent number: 10398716
    Abstract: Disclosed are methods of modulating and/or decreasing serum corticosterone levels in an individual affected by stress. Further disclosed are methods of modulating the hypothalamic pituitary adrenal response in an individual. The methods include administration of 2-fucosyl-lactose to an individual.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: September 3, 2019
    Assignee: ABBOTT LABORATORIES
    Inventors: Enrique Vazquez Hernandez, Ricardo Rueda Cabrera, Rachael Buck, Maria Ramirez Gonzalez
  • Patent number: 10398718
    Abstract: A new class of pseudo-trisaccharide aminoglycosides having an alkyl group at the 5? position, exhibiting efficient stop codon mutation readthrough activity, low cytotoxicity and high selectivity towards eukaryotic translation systems are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders, as well as processes of preparing these aminoglycosides. The disclosed aminoglycosides can be represented by the general formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group consisting of alkyl, cycloalkyl and aryl; and all other variables and features are as described in the specification.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: September 3, 2019
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Timor Baasov, Dana Atia-Glikin, Jeyakumar Kandasamy, Valery Belakhov
  • Patent number: 10392419
    Abstract: Compounds of formula (I) wherein Base1 and Base2 are defined as in claim 1 are modulators of STING.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 27, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thorsten Oost, Martin Fleck, Christian Andreas Kuttruff, Sebastian Carotta
  • Patent number: 10392414
    Abstract: Disclosed is a compound of formula (I): wherein R1, R2, R3, and are as defined herein. Also disclosed are methods for increasing mammalian cell NAD+ production and improving mitochondrial cell densities comprising administering to a cell the compound or a salt thereof.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: August 27, 2019
    Assignee: CORNELL UNIVERSITY
    Inventors: Anthony Sauve, Farheen Sultana Mohammed, Yue Yang
  • Patent number: 10385087
    Abstract: Disclosure of the present invention relates to a method for synthesis of a xylose derivative, which comprises protecting a xylose with a protective group, followed by incorporating to a halogen atom as a leaving group; removing the protective groups and using water-soluble ligands to carry out a Suzuki cross-couplings reaction with a palladium catalyst in a water solution. Ten new xylose derivatives as obtained by the method are also provided.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: August 20, 2019
    Assignee: NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY
    Inventor: Kuo-Yuan Hwa
  • Patent number: 10377761
    Abstract: Provided herein are formulations, methods and substituted tetrahydrofuranyl-pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds of Formula (I) for treating Pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of tetrahydrofuranyl-pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: August 13, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael O'Neil Hanrahan Clarke, Edward Doerffler, Richard L. Mackman, Dustin Siegel
  • Patent number: 10370400
    Abstract: This disclosure presents 4-MUG derivatives (e.g., 4-MUG ester prodrugs) that reduce or prevent HA synthesis. In some embodiments, the 4-MUG derivatives of the present disclosure can be used to suppress HA synthesis and curtail inflammation.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: August 6, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Nadine Nagy, Jayakumar Rajadas, Paul Bollyky
  • Patent number: 10370399
    Abstract: The invention relates generally to a calicheamicin molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody directly conjugated by a disulfide to one or more calicheamicin molecules.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: August 6, 2019
    Assignee: Genentech, Inc.
    Inventor: Thomas Pillow
  • Patent number: 10370401
    Abstract: Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: August 6, 2019
    Assignee: Janssen BioPharma, Inc.
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith, Marija Prhavc, Christian Andreas Jekle, Jerome Deval
  • Patent number: 10363262
    Abstract: The present invention relates to a composition for wound healing or skin regeneration comprising gypenoside 75 (gypenoside LXXV) as an active ingredient.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: July 30, 2019
    Assignee: INTELLIGENT SYNTHETIC BIOLOGY CENTER
    Inventors: Sun-Chang Kim, Sungjoo Park, Eun Su Ko
  • Patent number: 10364266
    Abstract: A compound of Formula (I) wherein Y1, Y2, X1, X2, R1, R2, R3, R4, R5, R6, R8, and R9 are as defined herein; and pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: July 30, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jerry Adams, Yiqian Lian
  • Patent number: 10363265
    Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: July 30, 2019
    Assignees: Idenix Pharmaceuticals LLC, Universita Degli Studi di Cagliari
    Inventors: Jean-Pierre Sommadossi, Paolo La Colla
  • Patent number: 10357507
    Abstract: The present invention provides a method of inhibiting renal fibrosis in a subject in need thereof.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: July 23, 2019
    Inventor: Sheau-Long Lee